Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25260084 | 0.80 | APP (0.51) | MAOBMAOADAONPC1RAB9A | |
| SCHEMBL30991743 | 0.80 | APP (0.51) | MAOBMAOADAONPC1RAB9A | |
| SCHEMBL28202737 | 0.79 | SMN1; SMN2 (0.49) | MAOBMAOADAOHSD17B10SCN9A | |
| SCHEMBL1828030 | 0.79 | MAOA (0.42) | MAOBMAOADAOHSD17B10SCN9A | |
| SCHEMBL24883472 | 0.79 | SCN9A (0.48) | MAOBMAOADAOHSD17B10SCN9A | |
| SCHEMBL14125786 | 0.79 | SMN1; SMN2 (0.43) | MAOBMAOADAOHSD17B10SCN9A | |
| SCHEMBL1830465 | 0.79 | SCN9A (0.48) | MAOBMAOADAOHSD17B10SCN9A | |
| SCHEMBL28039717 | 0.79 | MAOA (0.40) | MAOBMAOADAOHSD17B10SCN9A | |
| SCHEMBL11973719 | 0.79 | CYP11B1 (0.44) | MAOBMAOADAOHSD17B10SCN9A | |
| SCHEMBL24883423 | 0.78 | DAO (0.44) | MAOBMAOADAOHSD17B10SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993598-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993598-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993598-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8969387-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969387-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969387-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140031393-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031393-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20140031393-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8592597-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2318390-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2318390-A1 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010024451-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056577-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | MAOB 774/4885MAOA 1522/4885DAO 1901/4885 |
| US-20140031393-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | MAOB 774/4885MAOA 1522/4885DAO 1901/4885 |
| US-20110172275-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | MAOB 774/4885MAOA 1522/4885DAO 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.